Tumor-specific upregulation of human leukocyte antigen–G expression in bladder transitional cell carcinoma

Ling-hong, Gan; Huang, Lifu; Zhang, Xia; Lin, Aifen; Xu, Dan-Ping; Wang, Qing; Wang, Tianji; Yan, Wei‐Hua

doi:10.1016/j.humimm.2010.06.012

Cited by 21 publications

(17 citation statements)

References 43 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, significantly enhanced sHLA-G levels were proven to be useful in assisting the diagnosis of malignant versus healthy conditions. The area under the ROC for sHLA-G levels in plasma between patients and normal controls was 0.953 in bladder cancer [37], 0.739 in renal cell carcinoma [38], 0.95 in breast cancer [39], 0.84 in distinguishing colorectal cancer from benign colorectal diseases [40], and 0.992 in esophageal squamous cell carcinoma [41], respectively. In this study, sHLA-G levels among AHB, CHB, and RHB patients were found to be much higher than in normal controls.…”

Section: Discussionmentioning

confidence: 98%

Plasma soluble human leukocyte antigen-G expression is a potential clinical biomarker in patients with hepatitis B virus infection

Shi

Lin²,

et al. 2011

Human Immunology

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 98%

Plasma soluble human leukocyte antigen-G expression is a potential clinical biomarker in patients with hepatitis B virus infection

Shi

Lin²,

et al. 2011

Human Immunology

Self Cite

View full text Add to dashboard Cite

“…In most tumors, the increased HLA-G expression has been associated with advanced disease stages, shorter survival time, presence of metastasis, higher tumor grade, weak host immune response, greater tumor size, tumor recurrence, tumor invasion, poor histological grade, lower classical HLA antigen expression, presence of infiltrating T regulatory cells, cancer progression, increased inflammatory cell lesion infiltration, and tumor differentiation ( 23 , 24 , 26 , 29 – 32 , 34 – 36 , 40 – 42 , 44 , 46 – 48 , 50 – 54 , 56 , 57 , 66 , 69 , 72 , 73 , 79 ). In other tumors, no association between increased HLA-G expression and clinicopathological features has been observed, including bladder TCC ( 38 ) and acute myeloid leukemia ( 67 , 68 ).…”

Section: Tumorsmentioning

confidence: 99%

“…Increased HLA-G expression has been observed in different tumor types, including breast cancer ( 22 – 29 ), hepatocellular carcinoma ( 30 – 33 ), papillary thyroid carcinoma ( 34 , 35 ), follicular thyroid carcinoma ( 35 ), follicular adenoma ( 35 ), nasopharyngeal carcinoma ( 36 ), neuroblastoma ( 37 ), bladder transitional cell carcinoma (TCC) ( 38 ), melanoma ( 39 – 42 ), colorectal cancer ( 43 – 45 ), gastric cancer ( 46 – 48 ), esophageal carcinoma ( 49 – 53 ), lung cancer ( 49 , 54 – 57 ), renal cell carcinoma ( 58 – 62 ), glioblastoma ( 63 – 66 ), acute myeloid leukemia ( 67 , 68 ), and B-cell chronic lymphocytic leukemia ( 69 – 73 ). Table 1 summarizes the HLA-G expression in many types of tumors described in this review.…”

Section: Tumorsmentioning

confidence: 99%

The Role of HLA-G Molecule and HLA-G Gene Polymorphisms in Tumors, Viral Hepatitis, and Parasitic Diseases

et al. 2015

View full text Add to dashboard Cite

Considering that the non-classical HLA-G molecule has well-recognized tolerogenic properties, HLA-G expression is expected to be deleterious when present in tumor cells and in cells chronically infected by viruses, whereas HLA-G expression is expected to be advantageous in autoimmune disorders. The expression of HLA-G on tissue or peripheral blood cells, the levels of soluble HLA-G and polymorphic sites along the gene have been studied in several disorders. In this study, we revised the role of the molecule and polymorphic sites along the HLA-G gene in tumors, viral hepatitis, and parasitic disorders. Overall, several lines of evidence clearly show that the induction of HLA-G expression in tumors has been associated with worse disease outcome and disease spread. In addition, the few studies conducted on hepatitis and parasitic disorders indicate that HLA-G may contribute to disease pathogenesis. Few isolated polymorphic sites, primarily located at the coding or 3′ untranslated HLA-G region, have been evaluated in these disorders, and a complete HLA-G typing together with the study of gene regulatory elements may further help on the understanding of the influence of the genetic background on disease susceptibility.

show abstract

“…As a result of the mAb 5A6G7 could not discriminate the isoforms between HLA-G5 and HLA-G6 in immunohistochemistry analysis, a Western blot was used to investigate the pattern of HLA-G5 and HLA-G6 expression in lesions in this study, according to their molecular weight with 37 kD and 27 kD respectively [24]. We found that HLA-G5 is the main isoform of lesion sHLA-G expression, and this is strongly agreed to the results of immunohistochemistry as shown in Figure 1C.…”

Section: Discussionmentioning

confidence: 99%

Significance of tumour cell HLA‐G5/‐G6 isoform expression in discrimination for adenocarcinoma from squamous cell carcinoma in lung cancer patients

Yan

Liu

et al. 2015

J Cellular Molecular Medi

Self Cite

View full text Add to dashboard Cite

Human leucocyte antigen (HLA)-G has seven isoforms, of which HLA-G1-G4 are membrane-bound and HLA-G5-G7 are soluble. Previous studies reinforced HLA-G expression was strongly related to poor prognosis in different types of cancers. Among these studies, the monoclonal antibody (mAb) 4H84 was used which detects all HLA-G isoform heavy chain; unfortunately, leaves the specific types of isoforms expressed in lesions undistinguished and its clinical significance needs to be clarified. To explore clinical significance of lesion soluble HLA-G (sHLA-G) in non-small-cell lung cancer (NSCLC), mAb 5A6G7 recognizing HLA-G5/-G6 molecules was used. Tumour cell sHLA-G expression in 131 primary NSCLC lesions (66 squamous cell carcinoma, 55 adenocarcinoma and 10 adenosquamous carcinoma) were analysed with immunohistochemistry. Data showed that sHLA-G expression was observed in 34.0% (45/131) of the NSCLC lesions, which was unrelated to patient age, sex, lymph nodal status, tumour–node–metastasis stage and patient survival. However, tumour cell sHLA-G expression in lesions was predominately observed in adenocarcinoma lesions (73.0%, 40/55) which was significantly higher than that in squamous cell carcinoma (6.0%, 4/66) and adenosquamous carcinoma lesions (10.0%, 1/10, P < 0.001). The area under the receiver operating characteristic curve for lesion sHLA-G was 0.833 (95% CI: 0.754–0.912, P < 0.001) for adenocarcinoma versus squamous cell carcinoma. Our findings for the first time showed that tumour cell sHLA-G was predominately expressed in lung adenocarcinoma, which could be a useful biomarker to discriminate adenocarcinoma from squamous cell carcinoma in NSCLC patients.

show abstract

Tumor-specific upregulation of human leukocyte antigen–G expression in bladder transitional cell carcinoma

Cited by 21 publications

References 43 publications

Plasma soluble human leukocyte antigen-G expression is a potential clinical biomarker in patients with hepatitis B virus infection

Plasma soluble human leukocyte antigen-G expression is a potential clinical biomarker in patients with hepatitis B virus infection

The Role of HLA-G Molecule and HLA-G Gene Polymorphisms in Tumors, Viral Hepatitis, and Parasitic Diseases

Significance of tumour cell HLA‐G5/‐G6 isoform expression in discrimination for adenocarcinoma from squamous cell carcinoma in lung cancer patients

Contact Info

Product

Resources

About